450 related articles for article (PubMed ID: 29449184)
21. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease.
Rektorova I; Srovnalova H; Kubikova R; Prasek J
Mov Disord; 2008 Aug; 23(11):1580-7. PubMed ID: 18618663
[TBL] [Abstract][Full Text] [Related]
22. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
23. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
Lyoo CH; Ryu YH; Lee MJ; Lee MS
Acta Neurol Scand; 2012 Nov; 126(5):344-9. PubMed ID: 22380639
[TBL] [Abstract][Full Text] [Related]
24. Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease.
Moccia M; Pappatà S; Picillo M; Erro R; Coda AR; Longo K; Vitale C; Amboni M; Brunetti A; Capo G; Salvatore M; Barone P; Pellecchia MT
J Neurol; 2014 Nov; 261(11):2112-8. PubMed ID: 25119838
[TBL] [Abstract][Full Text] [Related]
25. Survival in Parkinson's disease in relation to striatal dopamine transporter binding.
Mäkinen E; Joutsa J; Vahlberg T; Kaasinen V
Parkinsonism Relat Disord; 2017 Sep; 42():66-72. PubMed ID: 28662820
[TBL] [Abstract][Full Text] [Related]
26. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
[TBL] [Abstract][Full Text] [Related]
27. Processing speed is related to striatal dopamine transporter availability in Parkinson's disease.
Vriend C; van Balkom TD; van Druningen C; Klein M; van der Werf YD; Berendse HW; van den Heuvel OA
Neuroimage Clin; 2020; 26():102257. PubMed ID: 32344372
[TBL] [Abstract][Full Text] [Related]
28. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease.
Iacovelli E; Gilio F; Meco G; Fattapposta F; Vanacore N; Brusa L; Giacomelli E; Gabriele M; Rubino A; Locuratolo N; Iani C; Pichiorri F; Colosimo C; Carbone A; Palleschi G; Inghilleri M
Mov Disord; 2010 Jul; 25(9):1203-9. PubMed ID: 20310046
[TBL] [Abstract][Full Text] [Related]
29. Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease.
Gigante AF; Asabella AN; Iliceto G; Martino T; Ferrari C; Defazio G; Rubini G
Neurol Sci; 2018 Mar; 39(3):551-555. PubMed ID: 29362953
[TBL] [Abstract][Full Text] [Related]
30. Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings.
Gigante AF; Defazio G; Niccoli Asabella A; Superbo M; Ferrari C; Liuzzi D; Iliceto G; Livrea P; Rubini G
Acta Neurol Scand; 2016 Oct; 134(4):265-70. PubMed ID: 26659996
[TBL] [Abstract][Full Text] [Related]
31. [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset.
Isaias IU; Benti R; Cilia R; Canesi M; Marotta G; Gerundini P; Pezzoli G; Antonini A
Neuroreport; 2007 Sep; 18(14):1499-502. PubMed ID: 17712282
[TBL] [Abstract][Full Text] [Related]
32. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
Lorberboym M; Treves TA; Melamed E; Lampl Y; Hellmann M; Djaldetti R
Mov Disord; 2006 Apr; 21(4):510-4. PubMed ID: 16250023
[TBL] [Abstract][Full Text] [Related]
33. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N
Brain; 2015 Oct; 138(Pt 10):2964-73. PubMed ID: 26209314
[TBL] [Abstract][Full Text] [Related]
34. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease.
Happe S; Baier PC; Helmschmied K; Meller J; Tatsch K; Paulus W
J Neurol; 2007 Aug; 254(8):1037-43. PubMed ID: 17351722
[TBL] [Abstract][Full Text] [Related]
35. White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
Jeong SH; Lee HS; Jung JH; Baik K; Lee YH; Yoo HS; Sohn YH; Chung SJ; Lee PH
Mov Disord; 2021 Jun; 36(6):1411-1419. PubMed ID: 33513293
[TBL] [Abstract][Full Text] [Related]
36. The pattern of FP-CIT PET in pure white matter hyperintensities-related vascular parkinsonism.
Lee YH; Lee S; Chung SJ; Yoo HS; Jung JH; Baik K; Ye BS; Sohn YH; Yun M; Lee PH
Parkinsonism Relat Disord; 2021 Jan; 82():1-6. PubMed ID: 33220520
[TBL] [Abstract][Full Text] [Related]
37. Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson's Disease.
Chung SJ; Lee S; Yoo HS; Lee YH; Lee HS; Choi Y; Lee PH; Yun M; Sohn YH
J Parkinsons Dis; 2020; 10(4):1541-1549. PubMed ID: 32925098
[TBL] [Abstract][Full Text] [Related]
38. Serotonin transporter binding and anxiety symptoms in Parkinson's disease.
Joling M; van den Heuvel OA; Berendse HW; Booij J; Vriend C
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):89-94. PubMed ID: 28899958
[TBL] [Abstract][Full Text] [Related]
39. Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET.
Chung M; Park YS; Kim JS; Kim YJ; Ma HI; Jang SJ; Huh R; Kim HS; Kim WC
Jpn J Radiol; 2015 Oct; 33(10):609-18. PubMed ID: 25952404
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Extrastriatal
Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
